Biotech and Mobility Firms Hit by Wave of Investor Lawsuits—What’s Behind the Legal Storm?

Biotech and Mobility Firms Hit by Wave of Investor Lawsuits—What’s Behind the Legal Storm?

2026-06-19 companies

New York, Friday, 19 June 2026.
Four high-profile companies—Erasca, Nano-X Imaging, PicS N.V., and Via Transportation—face securities class actions after allegations of misleading investors. Erasca’s stock plunged 54% following claims of patent infringement and hidden trial risks, while Via’s shares dropped ~70% after undisclosed growth setbacks. With deadlines looming for lead plaintiff roles, this surge in litigation signals heightened scrutiny of volatile sectors, where unproven technologies and regulatory hurdles collide with investor expectations.

The Lawsuits: Four Companies Under Fire

On June 19, 2026, four publicly traded companies—Erasca, Inc. (NASDAQ: ERAS), Nano-X Imaging Ltd. (NASDAQ: NNOX), PicS N.V. (NASDAQ: PICS), and Via Transportation, Inc. (NYSE: VIA)—found themselves at the center of securities class action lawsuits filed in New York courts [1][2][3][4]. The lawsuits, initiated by The Gross Law Firm and Levi & Korsinsky, LLP, allege violations of federal securities laws, including material misrepresentations and omissions that may have artificially inflated stock prices or concealed critical risks from investors [1][5]. These cases reflect a broader trend of heightened legal scrutiny targeting high-growth sectors, particularly biotechnology and mobility, where investor expectations often outpace technological or regulatory realities [GPT].

Erasca’s Plunge: Patent Risks and Hidden Trial Data

Erasca, Inc., a clinical-stage oncology company, faces allegations that it misled investors about the competitive positioning and intellectual property (IP) risks of its lead drug candidate, ERAS-0015. The lawsuit, filed by Levi & Korsinsky, LLP, covers shareholders who purchased ERAS stock between January 14, 2025, and April 26, 2026 [5]. Erasca’s stock price collapsed by -53.932%—from $21.49 to $9.90 per share—following disclosures that the company’s preclinical comparisons to Revolution Medicines’ RMC-6236 were allegedly flawed and carried undisclosed patent infringement risks [5]. The complaint specifically cites Erasca’s claim that ERAS-0015 demonstrated “8-21-fold higher binding affinity to cyclophilin A relative to RMC-6236” and “comparable antitumor activity at 1/10th of the dose,” which the lawsuit describes as “deceptive and untrue” [5]. Additionally, Erasca allegedly omitted a Grade 5 treatment-related adverse event—a patient death—in its Phase 1 safety data, further exposing the company to legal and reputational risks [5]. The company had raised $258.8 million in a stock offering that closed on January 23, 2026, a move the lawsuit suggests was timed to maintain an artificially inflated stock price [5].

Via Transportation: Growth Narratives and Regulatory Realities

Via Transportation, Inc., a mobility-as-a-service (MaaS) provider, is accused of overstating its growth trajectory and concealing regulatory and operational challenges in its core markets. The class action, filed by The Gross Law Firm, alleges that Via misled investors about its “successful land and expand strategy,” rapid revenue growth, and strong customer adoption [4]. The lawsuit claims that the company failed to disclose declines in Platform Annual Run-Rate Revenue (ARR) per customer, which were first reported on November 13, 2025, as well as structural and regulatory issues in Germany that hindered its ability to move beyond microtransit sales [4]. These disclosures, made on February 27, 2026, and May 12, 2026, coincided with a stock price decline of approximately 70%, according to investor alerts [4][alert! ‘Exact percentage decline not provided in sources’]. The class period for the lawsuit spans from September 15, 2025—the date of Via’s initial public offering (IPO)—to the present [4].

PicS N.V.: Credit Risks and IPO Disclosures

PicS N.V., a Brazilian financial technology company, faces allegations that it concealed material credit risks and operational deficiencies in the lead-up to its January 30, 2026, IPO. The lawsuit, filed by Holzer & Holzer, LLC, claims that PicS discovered deficient credit evaluation procedures in December 2025, leading to the reclassification of R$590 million in Stage 2 exposures to Stage 3—a move that triggered an R$88 million incremental expected credit loss (ECL) charge in the fourth quarter of 2025 [6]. The complaint further alleges that PicS experienced a Stage 3 formation rate exceeding 7% in Q4 2025, a deviation from historical trends that was not disclosed in its IPO documents [3][6]. Investors also claim that PicS overstated the quality of its credit models and underwriting abilities, while failing to disclose heightened customer credit risks and default incidents that were projected to worsen post-IPO [3][6]. The class period for the lawsuit includes all purchasers of PicS Class A common stock in or traceable to its January 30, 2026, IPO [3].

Nano-X Imaging: A Case Still Unfolding

Nano-X Imaging Ltd., an Israeli medical imaging technology company, is the fourth firm named in The Gross Law Firm’s recent wave of securities class action alerts. While details of the allegations remain sparse, the lawsuit likely centers on claims of material misrepresentations or omissions related to the company’s technological capabilities, regulatory approvals, or financial performance [2]. Nano-X has faced scrutiny in the past over its novel X-ray technology, which promises to reduce costs and improve accessibility in medical imaging [GPT]. The class period for the lawsuit spans from March 31, 2025, to April 17, 2026, with a lead plaintiff deadline set for August 11, 2026 [7]. Investors who purchased NNOX shares during this period are encouraged to contact The Gross Law Firm to explore their legal options [2][7].

For shareholders of the four companies, the clock is ticking to participate in the lawsuits as lead plaintiffs. The deadlines vary by case: August 4, 2026, for PicS N.V. [3][6], August 10, 2026, for Erasca and Via Transportation [1][4][5], and August 11, 2026, for Nano-X Imaging [2][7]. A lead plaintiff is typically the investor with the largest documented financial losses, who then oversees the litigation on behalf of the class [GPT]. Importantly, participation in the class action does not require lead plaintiff status, and investors may still seek recovery even if they do not apply to lead the case [1][3][4][5]. Law firms handling these cases, including The Gross Law Firm, Levi & Korsinsky, and Holzer & Holzer, operate on a contingency basis, meaning investors incur no upfront fees or costs [1][3][5][6].

The surge in securities class actions against biotech and mobility firms is not an isolated phenomenon. These sectors share several characteristics that make them particularly vulnerable to investor lawsuits: reliance on unproven or early-stage technologies, dependence on regulatory approvals, and high valuation multiples that leave little room for error [GPT]. In biotech, for example, companies often raise significant capital based on preclinical or early-phase clinical data, which may not translate into successful commercial products [GPT]. Erasca’s case highlights the risks of overpromising competitive advantages in a crowded oncology market, where IP disputes and safety concerns can derail even the most promising drug candidates [5]. Similarly, mobility firms like Via Transportation operate in highly regulated environments where shifts in local policies or market dynamics can quickly undermine growth projections [4]. The financial technology sector, represented by PicS N.V., faces its own set of challenges, including credit risk management and the accuracy of financial disclosures in emerging markets [3][6].

Corporate Governance and the Role of Shareholder Activism

These lawsuits underscore the growing influence of shareholder activism in holding companies accountable for their financial disclosures. Securities class actions serve as a critical mechanism for investors to seek redress when they believe they have been misled, and they can also drive improvements in corporate governance [GPT]. For instance, the allegations against PicS N.V. suggest a failure in internal controls, particularly in credit risk assessment and disclosure practices [3][6]. Similarly, Via Transportation’s case raises questions about the adequacy of its risk disclosures, especially regarding regulatory challenges in international markets [4]. For biotech firms like Erasca, the lawsuits highlight the need for greater transparency in preclinical data comparisons and IP risk assessments [5]. As these cases proceed, they may set precedents for how companies in volatile sectors communicate risks to investors, potentially leading to more conservative disclosures and stricter internal compliance measures [GPT].

Investor Confidence and Sector-Wide Implications

The wave of lawsuits could have far-reaching implications for investor confidence in the biotech and mobility sectors. High-growth industries often attract speculative investment, but the recent legal challenges may prompt a reassessment of risk among institutional and retail investors alike [GPT]. For biotech, the Erasca case serves as a cautionary tale about the dangers of overhyping preclinical data and underestimating IP risks [5]. In the mobility sector, Via Transportation’s legal troubles may lead investors to demand greater transparency about regulatory hurdles and customer adoption metrics [4]. The financial technology space, already grappling with credit risk management challenges, could see increased scrutiny of IPO disclosures following PicS N.V.’s alleged failures [3][6]. While securities class actions are a routine part of the financial landscape, the concentration of cases in these sectors suggests a need for companies to bolster their compliance and disclosure practices—or risk facing similar legal challenges in the future [GPT].

Sources


securities litigation shareholder lawsuits